Panitumumab after Resection of Liver Metastases from Colorectal Cancer in KRAS Wild-type Patients -PARLIM-

The study aims to assess the efficacy of postoperative therapy with FOLFOX plus panitumumab followed by maintenance with panitumumab for 3 months in KRAS wild-type patients, compared to the historical data for standard FOLFOX chemotherapy alone, which are verified by a randomised control group without the antibody.